ABSTRACT
Selinexor is the first selective inhibitor of nuclear export (SINE) to be approved for treatment of relapsed or refractory multiple myeloma (MM). There are currently no known genomic biomarkers or assays to help select MM patients at higher likelihood of response to selinexor. Here, we aim to characterize transcriptomic correlates of response to selinexor-based therapy, and present a novel, three-gene expression signature that predicts selinexor response in MM. We analyzed RNA sequencing of CD138+ tumor cells from bone marrow of 100 MM patients who participated in the BOSTON study and identified three genes upregulated in responders. Then, we validated this gene signature in 64 patients from the STORM cohort of triple-class refractory MM, and additionally in an external cohort of 35 patients treated in a real world setting outside of clinical trials. We also found that the signature tracked with response in a cohort of 57 patients with recurrent glioblastoma treated with selinexor. Furthermore, the genes involved in the signature, WNT10A, DUSP1, and ETV7, reveal a potential mechanism through upregulated interferon-mediated apoptotic signaling that may prime tumors to respond to selinexor-based therapy. This signature has important clinical relevance as it could identify cancer patients that are most likely to benefit from treatment with selinexor-based therapy.
Competing Interest Statement
This study was supported by Karyopharm Therapeutics. YL reports being employed by and owning stock in Karyopharm Therapeutics. CW reports being employed by Karyopharm Therapeutics. AC reports receiving grant support and consulting fees from Millennium/Takeda, grant support, advisory board fees, and consulting fees from Celgene, Novartis Pharmaceuticals, Amgen, and Janssen, consulting fees from Bristol-Myers Squibb, advisory board fees from Sanofi and Oncopeptides, grant support from Pharmacyclics, and grant support and advisory board fees from Seattle Genetics. DM reports current employment by Janssen. HJC reports research support from Bristol-Myers Squibb and Takeda. JR reports receiving consulting fees and fees for serving on a speakers bureau from Amgen, advisory board fees and fees for serving on a speakers bureau from Celgene, Takeda, and Janssen, and advisory board fees from Sanofi, Karyopharm Therapeutics, Oncopeptides, Adaptive Biotechnologies, and Bristol-Myers Squibb. SR reports receiving consulting fees from Karyopharm Therapeutics, Janssen Pharmaceuticals, and Bristol-Myers Squibb. SJ reports receiving advisory board fees and consulting fees from Celgene, Bristol-Myers Squibb, Janssen Pharmaceuticals, and Merck. SP reports receiving grant support from Karyopharm Therapeutics.
Funding Statement
This study was supported by Karyopharm Therapeutics.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Mount Sinai institutional review board (IRB) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
This version of the manuscript has been updated to add clarification to the main figures 1, 2 and 3. Ordinal regression analysis is included in figure 3 and replaces the Wilcoxon test sub-panels. siRNA validation experiments are removed from this version of the manuscript; and the text has been updated accordingly. Author list and affilations are updated. Minor typos are also fixed.
Data Availability
Raw sequencing data will be deposited in SRA upon publication. The code necessary to calculate selinexor signatures is provided in a GitHub repository at https://github.com/Lagana-Lab/selinescore.
